Stem Cell Transplantation

NEW ORLEANS — Utilization of hematopoietic stem cell transplantation for acute myeloid leukemia has increased over time but remains far below optimal levels, according to study results presented at ASH Annual Meeting and Exposition.

Patients with multiple myeloma who receive high-dose chemotherapy followed by autologous stem cell transplantation may experience diminished quality of life due to acute life disruptions and symptom burden.

A patient aged 72 years with high-risk myelodysplastic syndrome presents at a community hematology/oncology clinic.

Koen van Besien, MD, PhD, has been appointed chief of the division of hematology at University Hospitals Seidman Cancer Center.

In this video, Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses the phase 3 DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.

Multiple myeloma is the most common indication for autologous stem cell transplantation worldwide.

The last 3 years of drug development in scleroderma have come to represent everything that ails the current pipeline for that disease.

WEST PALM BEACH, Florida — Autologous hematopoietic stem cell transplantation had long-term effectiveness for treating aggressive MS, according to results of a retrospective observational study presented at the ACTRIMS Forum.

The regenerative capacity of stem cells has been of great interest in every field of medicine.

Sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative allogeneic peripheral blood stem cell transplantation, according to phase 2 study results published in The New England Journal of Medicine.